MÖMuharrem Özden

Muharrem Özden

*This is an algorithmically generated author record based on publicly available information.

Muharrem Özden has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of sennoside A + B and sodium picosulfate-based regimens for bowel preparation: a prospective randomized trial

    by İ. Durak, M. Özden, T. Düzenli, M. Sadeçolak, M. Kaya, H. Köseoğlu

    Aim: Adequate bowel preparation is essential for high-quality colonoscopy and directly affects key quality indicators such as adenoma detection and cecal intubation. Although low-volume, nonpolyethylene glycol (PEG) regimens are widely used in clinical practice, real-world comparative data between stimulant-based preparations and sodium picosulfate-based combinations remain limited. This study aimed to compare the effectiveness and tolerability of sennoside A + B versus sodium picosulfate/magnesium oxide/citric acid (PM/Ca) using the Boston Bowel Preparation Scale (BBPS). Methods: This prospective, randomized, observer-blinded trial included adults aged 18–80 years undergoing elective outpatient colonoscopy. Participants were randomized 1:1 to receive either sennoside A + B oral solution (split-dose: 250 mL at 21:00 and 250 mL at 23:00) or PM/Ca (two sachets at 19:00 and 21:00), both administered with a low-residue diet and written instructions; rectal enemas were applied as part of the institutional protocol. Bowel cleanliness was assessed using BBPS. Adequate preparation was defined as BBPS > 6. Multivariable logistic regression was performed to identify independent predictors of adequate preparation. Results: A total of 705 patients were included in the primary analysis cohort (341 sennoside A + B; 364 PM/Ca). Adequate bowel preparation (BBPS > 6) was achieved more frequently in the sennoside A + B group than in the PM/Ca group (70.1% versus 56.3; p < 0.001), and the mean BBPS score was higher (6.64 ± 1.78 versus 5.93 ± 1.92; p < 0.001). Polyp detection rates were similar between groups (21.4% versus 26.6; p = 0.138). In multivariable analysis, higher education (OR 1.38; 95% CI 1.06–1.81; p = 0.016) and sennoside A + B (OR 1.77; 95% CI 1.29–2.43; p < 0.001) were independent predictors of adequate preparation, whereas age, BMI, sex, diabetes mellitus, and constipation were not. Preparation intolerance was more frequent in the sennoside A + B group (7.0% versus 0.7%; p < 0.001; tolerance analysis n = 824). Failure to reach the cecum did not differ significantly between regimens (9.3% versus 12.3%; p = 0.216; analyzed in the entire study population n = 791). Conclusions: In routine clinical practice, sennoside A + B provided higher cleansing efficacy than PM/Ca as reflected by higher BBPS scores and a greater probability of achieving adequate bowel preparation. However, PM/Ca demonstrated a more favorable tolerability profile. Bowel preparation selection should balance efficacy and tolerability while considering patient-related factors such as educational level. Trial registration: ClinicalTrials.gov, NCT06580366.

  • Open Access

    Relationship of Serum Pro-Gastrin-Releasing Peptide with Kidney Fibrosis and Proteinuria

    by Muharrem Özden, Barış Eser, İbrahim Doğan, Nihal Aydemir, Aysel Çolak, Hüseyin Kayadibi, Gamze Kodalak Özil, Berkant Bebek, Alpaslan Karabulut

    Background: Interstitial fibrosis/tubular atrophy (IFTA) plays a crucial role in the pathogenesis of chronic kidney disease. Pro-gastrin-releasing peptide (proGRP), a neuropeptide, plays a role in stimulating fibroblast activity. This study explores the association between serum proGRP levels and IFTA severity. Methods: The patient group consisted of 49 patients (23 males; mean age 44.1 ± 15 years) who underwent kidney biopsy and the control group comprised 20 healthy volunteers (8 males; mean age 43.4 ± 7.2 years). Pro-gastrin-releasing peptide was measured using a commercially available Elabscience Human Pro-Gastrin-Releasing Peptide enzyme-linked immuno sorbent assay kit. The scoring system was implemented based on the percentage of IFTA severity in kidney tissue samples. Results: Pro-gastrin-releasing peptide levels were observed to be significantly elevated in the patient group compared to the controls [30.0 (22.1-48.1) U/L vs 19.7 (15.1-30.3) U/L, (P = .004)]. A statistically significant positive correlation was identi fied between proGRP level and the presence of proteinuria (P = .012). Conclusion: The study demonstrated that proGRP levels might increase in the presence of kidney fibrosis and proteinuria. Cite this article as: Özden M, Eser B, Doğan I, et al. Relationship of serum pro-gastrin-releasing peptide with kidney fibrosis and proteinuria. Turk J Nephrol. 2026;35(1):32-39.